Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis.
The relevance of animal models in multiple sclerosis research.
Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis.
Birth Outcomes in Newborns Fathered by Men with Multiple Sclerosis Exposed to Disease-Modifying Drugs.
Biogen Idec reports positive top-line results from Phase 2 anti-LINGO-1 trial in people with acute optic neuritis
Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis.
Synthetic Biologics Reports UCLA Announcement of Preliminary Positive Topline Efficacy and Safety Results from Investigator-Led Phase II Study of Trimesta™ for RRMS
Sex ratio of multiple sclerosis and clinical phenotype.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System.
Therapeutic plasma exchange and pregnancy: A case report and guidelines for performing plasma exchange in a pregnant patient.
Clinically isolated syndrome - Rethinking the diagnosis.
HLA-DRB1*15:01 and multiple sclerosis: a female association?
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
T(H)17 cytokines in autoimmune neuro-inflammation.
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
The MS Microbiome Consortium (MSMC): an academic multi-disciplinary collaborative effort to elucidate the role of the gut microbiota in MS
Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
Best practice in the use of natalizumab in multiple sclerosis.
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
Management of worsening multiple sclerosis with mitoxantrone: a review.
Suppressed RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis.
Neuroprotection mediated through estrogen receptor-alpha in astrocytes.
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort.
Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair

Pages